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Abstract
Background: The human SLC30A8 gene encodes the secretory granule-localised zinc transporter ZnT8 whose
expression is chiefly restricted to the endocrine pancreas. Single nucleotide polymorphisms (SNPs) in the human
SLC30A8 gene have been associated, through genome-wide studies, with altered type 2 diabetes risk. In addition
to a role in the control of insulin release, recent studies involving targeted gene ablation from the pancreatic α
cell (Solomou et al., J Biol Chem 290(35):21432-42) have also implicated ZnT8 in the control of glucagon release.
Up to now, however, the possibility that increased levels of the transporter in these cells may impact glucagon
secretion has not been explored.
Methods: Here, we use a recently-developed reverse tetracyline transactivator promoter-regulated ZnT8 transgene
to drive the over-expression of human ZnT8 selectively in the α cell in adult mice. Glucose homeostasis and
glucagon secretion were subsequently assessed both in vivo during hypoglycemic clamps and from isolated
islets in vitro.
Results: Doxyclin-dependent human ZnT8 mRNA expression was apparent in both isolated islets and in
fluorescence-activated cell sorting- (FACS) purified α cells. Examined at 12 weeks of age, intraperitoneal
glucose (1 g/kg) tolerance was unchanged in transgenic mice versus wild-type littermates (n = 8-10 mice/genotype,
p > 0.05) and sensitivity to intraperitoneal insulin (0.75U/kg) was similarly unaltered in transgenic animals. In contrast,
under hyperinsulinemic-hypoglycemic clamp, a ~45 % (p < 0.001) reduction in glucose infusion rate was apparent,
and glucagon release was significantly (~40 %, p < 0.01) impaired, in transgenic mice. Correspondingly,
examined in vitro, glucagon secretion was significantly reduced (~30 %, p < 0.05) from transgenic versus
control islets at low, stimulatory glucose concentrations (1 mM, p < 0.05) but not at high glucose (17 mM)
glucose (p > 0.05). Over-expression of ZnT8 in glucagonoma-derived αTC1-9 cells increased granule free
Zn2+ concentrations consistent with a role for Zn2+ in this compartment in the action of ZnT8 on glucagon
secretion.
Conclusions: Increased ZnT8 expression, and a likely increase in intragranular free Zn2+ concentration, is
deleterious in pancreatic α cells for stimulated glucagon release. These data provide further evidence that
type 2 diabetes-associated polymorphisms in the SLC30A8/ZnT8 gene may act in part via alterations in glucagon
release and suggest that ZnT8 activation may restrict glucagon release in some settings.
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Background
Type 2 diabetes mellitus (T2D) is a complex polygenic
disease which affects ~ 1 in 12 of the adult population
and consumes ~10 % of the health care budgets of most
westernized societies [1]. Although genome-wide associ-
ation (GWA) and other studies have in recent years
identified multiple loci as affecting the risk T2D [2, 3],
functional work in model systems remains important if
we are fully to understand the physiological role(s), and
potential as pharmacotherapeutic targets, of the impli-
cated genes. Most such studies up to now have used
gene deletion in mice, inactivating candidates either glo-
bally or in disease-relevant tissues [4, 5]. In the case of
the endocrine pancreas-restricted secretory granule zinc
transporter SLC30A8/ZnT8, identified in GWA studies
for T2D [6], this approach has been pivotal in highlight-
ing the role of the transporter in the control of secretory
granule formation and Zn2+ storage [7, 8] insulin secre-
tion [9] and hepatic clearance of the hormone [10].
Nevertheless, the impact of SLC30A8 risk variants [2]
on ZnT8 activity and T2D risk are still debated. The
common risk variant rs13266634 in the SLC30A8 gene
encodes an amino acid exchange (R325W) which is be-
lieved to lower transporter activity [7, 11]. On the other
hand, rare truncating variants of ZnT8 are protective
[12]. The reasons for this complex relationship between
ZnT8 levels and disease risk are not fully understood
[13, 14]. Whilst the role of the transporter in the control
of insulin secretion has been the chief focus of interest
in recent years, the observation that ZnT8 is also
expressed in the α cell in both rodents [7] and humans
[15] leads to the possibility that an action via glucagon
release may also affect diabetes risk. Indeed, Zn2+ ions
have been shown by autometallography [16] to be
present in the secretory granule of α as well as β cells.
Correspondingly, we have recently shown, by α cell-
selective deletion of ZnT8 in mice [17], an important
role for this transporter in the control of glucagon
secretion.
Importantly, and as well as providing insights into the
aetiopathology of T2D, changes in the normal release of
glucagon may also have consequences for glycemic
control in Type 1 diabetes (T1D). In the latter disease,
inadequate responses to hypoglycaemia constitute a sub-
stantial risk and limit the use of insulin treatment to
achieve good glycemic control and minimize disease
complications [18].
Although investigating the impact of the absence of a
gene is usually highly informative, its overexpression
may also provide important insights, particularly with
respect to the possible impact of pharmacological ap-
proaches which activate the gene or its product. Indu-
cible expression systems are consequently often used in
mice to achieve both temporal and spatial (i.e. tissue-
specific) control of the expression of a given gene. Com-
ponents of the Tet Switches [19] originate from the
tetracycline (Tet) resistance operon in E.coli and belong
to one of the most evolved gene regulation systems.
“Tet-Off” and “Tet-On” systems are used in the majority
of the studies involving inducible expression. The Tet-
Off system was initially developed in 1992 and in the
presence of the antibiotic tetracycline the expression
from a Tet-inducible promoter is decreased [19].
In order to utilize tetracycline as a regulator of tran-
scription, a tetracycline-controlled transactivator (tTA) is
controlled by fusion of the tetracycline repressor with a
transcriptional activation domain from Herpes Simplex
Virus (HSV). Thus, in the absence of tetracycline, the
fusion protein can bind tet operator sequences and pro-
mote transcription while in the presence of the anti-
biotic, its binding to the protein makes it unable to bind
DNA leading to a decrease in gene expression. The
“Tet-On” system was later developed by mutation of the
repressor portion of the tTA to create a reverse tetracyc-
line controlled transactivator (rtTA) that relies on tetra-
cycline for induction of gene expression rather than
repression [20]. The system was first used in the pancre-
atic β-cell by Efrat and colleagues [21] and about ten
years later in the α-cell [22].
Recently, our laboratory used this approach to deter-
mine the effects of ZnT8 over-expression in the pancre-
atic β-cell in mice, driving rtTA expression with the rat
insulin 2 promoter [23]. In the present study, the rtTA
sequence was placed under the control of the preproglu-
cagon promoter in Glu-rtTA mice [22] allowing us to
drive the expression of ZnT8 selectively in the α-cell in
the adult mouse.
Using this approach we have investigated the effect of
ZnT8 overexpression on glucagon secretion. Glu-rtTA
mice were therefore crossed to mice bearing a human
ZnT8 transgene whose expression was driven by the tet
operator sequence. In contrast to the recently described
effect of α cell-selective deletion of ZnT8 to enhance
glucagon secretion at low glucose [17], we demonstrate
that ZnT8 over-expression results in the suppression of
glucagon release during hypoglycaemia, consequently
enhancing glucose clearance.
Methods
Materials
Chemicals and biochemical were purchased from Sigma-
Aldrich (Poole, Dorset, U.K.) unless otherwise indicated.
Generation and genotyping of αZnT8Tg mice
Glu-rtTA mice, which possess a 1.1 kb region of the pre-
proglucagon promoter upstream of rtTA [22], were crossed
to animals bearing a human ZnT8-overexpressing trans-
gene (ZnT8Tg) as described in [23]. Heterozygous Glu-
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rtTA mice were crossed to homozygous ZnT8Tg animals.
Two ZnT8Tg founders were used, corresponding to lines
#31 and #23 in [23]. The litters comprised Glu-rtTA off-
spring, which expressed the human ZnT8 transgene after
induction with docycycline (as described below), while
littermates bearing the ZnT8Tg allele alone, and born at
Mendelian frequency (50 %), were used as controls. Doxy-
cyclin, a tetracycline derivative, was given to all experimen-
tal mice in the drinking water (2 g/L) from the age of six
weeks in order to induce ZnT8 expression in Glu-rtTA
+:ZnT8Tg+ animals [22]. Animals were kept in a pathogen-
free facility under a 12 h light-dark cycle with access to
water and a standard mouse diet (Lillico Biotechnology).
After weaning at 3–4 weeks of age mice were housed two
to five per cage. All strains were maintained on a C57/
BL6/J background.
Genotyping for Glu-rtTA was performed using stand-
ard PCR on DNA extracted from ear biopsies (Fig. 1a)
using the primers indicated in Table 1. For the ZnT8
transgene, qPCR was used to detect the presence in the
genome of the firefly luciferase gene, included in the
transgene in the antisense direction with respect to
ZnT8 cDNA [23].
Islet isolation and culture
Mice were sacrificed by cervical dislocation and islets
isolated essentially as described [24]. In brief, pancreata
were inflated with collagenase solution at 1ug/ml (Serva)
and placed in a water bath at 37 °C for 10 min. After
centrifugation and washing islets were purified on a
Histopaque 119 (Sigma) gradient, by centrifugation at
2500 rpm for 20 min. The islet layer was recovered and
islets cultured in complete RPMI 1640 medium (Gibco;
11 mM glucose) for 2–4 h at 37 °C islets before hand-
picking into fresh media.
Islet dissociation, fluorescence-activated cell sorting
(FACS) and FACS analysis
FACS analysis was performed essentially as described
[17]. After overnight incubation, 250–300 islets of the
same genotype were handpicked and dissociated into
single cells by repeated pipetting in 150 μl of Hank’s
based cell dissociation buffer (Invitrogen) containing
0.1 % BSA and 0.1 % trypsin. The reaction was
stopped with the addition of FBS (20 μl; Seralab).
Cells were incubated in near-IR dead cell stain (Life
technologies) for 20 min. at 4 °C, washed with PBA
(PBS, 1 % BSA, 0.1 % azide) and fixed in 2 % (w/v)
PFA for 10 min. and then washed twice with PBA
and once with Saponin (0.025 % in PBA) before
10 min incubation with Saponin at room temperature.
Cells were incubated with primary antibodies against
insulin or glucagon (see Table 2) before incubation
with secondary antibodies (anti-mouse AF 405, anti-
guinea pig AF 488, anti-rabbit AF 640) for 20 min
and resuspension in PBA. The samples were run on a
BD Fortessa Flow Cytometer (BD Bioscience).
RNA extraction and cDNA synthesis
Islets were washed once in phosphate-buffered saline
(PBS) followed by addition of TRIzol (ThermoFisher).
Chloroform (200 μl per ml of TRIzol) was added and
after centrifugation the upper aqueous phase was re-
moved and RNA was precipitated by adding 400 μl iso-
propanol per ml of TRIzol. After re-centrifugation and
washing the dried pellet was finally resuspended in
nuclease-free water. The same quantity of RNA was
used from each sample to perform a reverse transcrip-
tion polymerase chain reaction (RT-PCR) and cDNA
synthesis using random primers. cDNA was generated
from RNA (up to 1 μg) using a High Capacity Reverse
Transcription kit (Applied Biosystems) according the
manufacturer’s instructions using the following thermo-
cycler protocol: 10 min 25 °C, 2 h 37 °C, 5 min. 85 °C,
hold 4 °C.
Quantitative PCR (qPCR)
For gene expression measurements cDNA (2 μl) from
the RT-PCR reaction above were used as template for
quantitative Real Time PCR (qPCR) using a Fast
SYBR Green Master Mix (Invitrogen) according to
the manufacturer’s instructions. The reaction was ini-
tiated at 50 °C for 2 min. followed by the activation
and pre-denaturation step at 95 °C for 10 min. The
run was made up of 40 cycles of 15 s at 95 °C and
1 min. at 60 °C.
αTC1.9 cell transfection
αTC1.9 cells were transfected with a human ZnT8
(W325 variant) expression vector or with the corre-
sponding empty vector (EV), using Lipofectamine2000
(LifeTechnologies) as previously described [25, 26] and
according to the manufacturer’s instruction. For cyto-
solic Zn2+ measurement, cells were co-transfected with
an eCALWY-4 [27] expression vector. Imaging experi-
ments were performed the day after transfection.
Cytosolic Zn2+ measurement with eCALWY-4
Cells on coverslips were washed twice in Krebs-HEPES-
bicarbonate (KHB) buffer (140 mM NaCl, 3.6 mM KCl,
0.5 mM NaH2PO4, 0.2 mM MgSO4, 1.5 mM CaCl2,
10 mM HEPES, 25 mM NaHCO3), which was warmed,
bubbled with 95:5 O2/CO2, set to pH 7.4, and contained
11 mM glucose. Imaging of [Zn2+] using eCALWY sen-
sors [27] was carried out as optimized before [25, 26].
Briefly, cells were maintained at 37 °C throughout with a
heating stage (MC60, LINKAM, Scientific Instruments),
and KHB was perifused (1.5 to 2 mL/min) with additions
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Fig. 1 (See legend on next page.)
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as stated in the figures. Images were captured at 433 nm
monochromatic excitation wavelength (Polychrome IV,
Till photonics) using an Olympus IX-70 wide-field
microscope with a 40×/1.35NA oil immersion objective
and a zyla sCMOS camera (Andor Technology) con-
trolled by Micromanager software. Acquisition rate was
20 images/min. Emitted light was splitted and filtered by
a Dual-View beam splitter (Photometrics) equipped with
a 505dcxn dichroic mirror and two emission filters
(Chroma Technology, D470/24 for cerulean and D535/
30 for citrine). Image analysis was performed with Ima-
geJ software using a homemade macro and the fluores-
cence emission ratios were derived after subtracting
background. Steady-state fluorescence intensity ratio cit-
rine/cerulean (R) was measured, then maximum and
minimum ratios were determined to calculate free Zn2+
concentration using the following formula: [Zn2+] =
Kd(Rmax – R)/(R – Rmin). The maximum ratio (Rmax)
was obtained upon intracellular zinc chelation with
50 μM TPEN and the minimum ratio (Rmin) was obtain
upon zinc saturation with 100 μM ZnCl2 in the presence
of the Zn2+ ionophore, pyrithione (5 μM).
Granular Zn2+ Imaging with Zinpyr-4
αTC1.9 cells were incubated for 20 min. before imaging
in 1 μM Zinpyr-4 (Santa Cruz Biotechnology), and
washed twice in imaging buffer. Acquisitions were per-
formed as described above with additions as stated on
the figures. Zinpyr-4 was excited at 488 nm wavelength
and signal was collected through a 535/50 nm emission
filter. Differences in Zinpyr4 mean intensity between EV
and ZnT8-expressing cells were measured using ImageJ.
Other methods
Glucagon secretion was measured from islets essen-
tially as described in detail in [17]. In brief, 18 size-
matched islets per condition were incubated with
constant agitation for 1 h in 0.5 mL Krebs-HEPES bi-
carbonate buffer at 37 °C with either 1 mM or
17 mM glucose, and total and secreted glucagon mea-
sured at the end of the incubations by radioimmuno-
assay (Millipore). Details of intraperitoneal glucose
(1 g/kg; IPGTT) and insulin (0.5 U/kg; IPITT) tolerance
tests, and hypoglycemic clamps are provided in [17].
Statistics
Student’s t test was used to identify differences between
two independent variables and assessments between
multiple variables assessed by two-way ANOVA (with
suitable correction from multiple tests), followed by
Bonferroni’s post hoc test. All analyses were performed
using GraphPad Prism 6.0, and p < 0.05 was considered
significant. Values are presented as means ± S.E.
Results
Expression of human ZnT8 in transgenic islets
Initially to check that the administration of doxycyclin
was effective in inducing the overexpression of ZnT8,
total RNA was extracted from isolated islets incubated
overnight with doxycyclin (5 μg/ml). qPCR analysis re-
vealed expression of the human form of ZnT8 in the
mice containing both the overexpressing transgene and
Table 2 Antibodies
Primary
Antibody Species Company Dilution
ZnT8 Rabbit Mellitech 1:200
Glucagon Mouse Sigma 1:1000
Glucagon Rabbit Santa Cruz 1:200
Insulin Guinea pig Santa Cruz 1:200
Secondary
Antibody Species Company Dilution
Anti-mouse Alexa 568 Goat Invitrogen 1:1000
Anti-rabbit Alexa 488 Goat Invitrogen 1:1000
Anti-guinea pig Alexa 488 Donkey Invitrogen 1:1000
Anti-mouse Alexa 488 Donkey Invitrogen 1:1000
Anti-rabbit 568 Goat Invitrogen 1:1000
Table 1 PCR primers
Gene Sequence
β Actin FOR: CGAGTCGCGTCCACCC
REV: CATCCATGGCGAACTGGTG
Glucagon FOR: CCAAGAGGAACCGGAACAAC
REV: CCTTCAGCATGCCTCTCAAAT
Human ZnT8 FOR: CTGTCATCGAAGCCTCCCTC
REV: AAGGGCATGCACAAAAGCAG
Glu-rtTA FOR: CATAAACGGCGCTCTGGAATTACTCAATGGAGTCG
REV: GCCGAGATGCACTTTAGCCCCGTCGCGATGTGAGA
Luciferase FOR: CAACTGCATAAGGCTATGAAGAGA
REV: ATTTGTATTCAGCCCATATCGTTT
(See figure on previous page.)
Fig. 1 Overexpression of human ZnT8 in the α cell. a Genotyping by PCR. The Glu-rtTA transgene was amplified by standard PCR to identify con-
trol and transgenic animals. Lanes derived from control (lacking the GlrTTA transgene) mice are indicated with arrows as “C”. Samples from
transgene-bearing mice are present in lanes 1,2,4,6,7,9,11. b Human ZnT8 expression in isolated islets. Total RNA was extracted from islets from
control and transgenic mice. The levels of hZnT8 were assessed by RT-qPCR. c Human ZnT8 expression in purified α-cells. RNA was ex-
tracted from α-cells obtained from control or αZnT8Tg mice. The levels of hZnT8 mRNA were assessed by RT-qPCR
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the Glu-rtTA but not in the control mice carrying only
the ZnT8 transgene (Fig. 1b). We tested both founders
that carried the transgene and observed that only
founder 2 (#31 from [23]) expressed detectable levels of
human ZnT8. Consequently, offspring from this founder
was used in all in experiments.
In order to obtain a more accurate assessment of the
degree of overexpression in a pure α-cell population and
as opposed to islets, which are largely composed of β-
cells [28], isolated islets were dissociated and stained
with glucagon for fluorescence-activated cell sorting
(FACS). RNA was then extracted from the sorted cells to
check for expression of the human ZnT8 in the α-cells
obtained from transgenic and control animals (Fig. 1c).
Whilst essentially absent from non-transgenic islets,
hZnT8 mRNA was readily detected in islets from trans-
genic animals.
Intraperitoneal glucose and insulin tolerance are
unaltered in αZnT8Tg mice
To assess whether glucose homeostasis in transgenic
mice was altered, intraperitoneal glucose tolerance tests
(IPGTTs) were performed on male (Fig. 2a) and female
(Fig. 2b) mice aged 8 weeks. In neither case were any
differences in the excursions in blood glucose observed
between control and transgenic animals at any time
point during the tests.
Insulin sensitivity was similarly determine by intraperi-
toneal insulin tolerance tests (ITTs) were performed on
transgenic and control male (Fig. 2c) and female (Fig. 2d)
mice at the age of 14 weeks. Again, no differences were
observed between the responses of αZnT8Tg and con-
trol mice.
Trangenic mice require an elevated glucose infusion rate
(GIR) and display impaired glucagon secretion during
hypoglycemic clamps
ITTs as described above could only be used safely (i.e.
without life-threatening hypoglycaemia) to provide a
limited decrease in blood glucose levels (to ~ 4 mM),
above the usual threshold for substantial glucagon re-
lease in the mouse [29]. In order to elicit a more
marked, but stable, decrease in blood glucose levels,
where glucagon release is likely to be more strongly
stimulated, hypoglycaemic clamps [17] were performed.
Male mice were thus rendered hypoglycaemic by con-
tinuous intravenous administration of insulin (Fig. 3a).
Under these conditions ZnT8-overexpressing mice
Fig. 2 Glucose and insulin tolerance in αZnT8Tg mice. Intraperitoneal glucose tolerance tests were performed on control and transgenic male
(a) and female (b) mice at 8 weeks of age. n = 8–10 mice/genotype. Animals were fasted for 16 h before injection of 1 g/kg glucose. Blood
glucose was sampled after venisection of the tail vein at the indicated times, and quantified using an automated glucometer (AccuCheck, Roche).
c, d Insulin sensitivity. Intraperitoneal insulin tolerance tests performed on 12 week old male (c) and female (d) mice fasted for 5 h and injected
with 0.5U/kg insulin. n = 9–10 mice per genotype. Blood sampling was performed as in (a, b)
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required a significantly higher glucose infusion rate
(GIR) to maintain hypoglycaemia compared to control
mice (Fig. 3b), suggesting an impairment in glucagon re-
lease. Plasma glucagon levels were consequently mea-
sured prior to the onset of hypoglycaemia and at
120 min. after the beginning of insulin infusion (Fig. 3c).
Whilst no differences were observed between gluca-
gon levels in control and transgenic mice at the earl-
ier time point, concentrations of the hormone at
120 min were ~45 % lower (p < 0.01) in transgenic
versus control mice (Fig. 3c).
Glucagon secretion is impaired in islets isolated from
αZnT8Tg mice
We sought next to determine whether the impaired glu-
cagon secretion observed in vivo in αZnT8Tg mice
chiefly reflected a cell autonomous effect in the α-cell,
or a more complex set of changes in the autocrine re-
sponse to hypoglycaemia, potentially involving multiple
tissues (brain, adrenals etc.) [30, 31]. Correspondingly,
we observed that when isolated islets were incubated in
1 mM glucose (a concentration in the range which
strongly stimulates glucagon release from α-cells)
[29], those overexpressing ZnT8 secreted significantly
less (~20 %, p < 0.05) glucagon that control islets
(Fig. 4). At 17 mM glucose the responses did not dif-
fer between islets expressing ZnT8 selectively in the
α-cell and control islets.
Impact of ZnT8 over-expression on granular and cytosolic
free Zn2+ concentrations in clonal α-cells
In order to determine whether ZnT8 overexpression
may act via changes in subcellular free Zn2+ concentra-
tions, we monited the latter in secretory granules (Fig. 5)
Fig. 3 Elevated glucose infusion rates in αZnT8 KO mice during hypoglycaemic hyperinsulinaemic clamps. Experiments were performed on
12 week old male mice. Animals were fasted for 4 h and rendered hypoglycaemic by infusion of insulin (a). Glucose levels were monitored and
glucose infusion rate adjusted accordingly to keep the mice in a hypoglycaemic state at ~60–70 % of the initial value (b). c Blood was collected
from tail vein at times 0 and 120 min in tubes filled with EGTA (1.6 mg/ml, Sigma) and aprotinin (250 k-international units/ml; Sigma) for glucagon
measurement..n = 4 mice per genotype. Data are mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.005. Other details are given in the Methods section
Fig. 4 Glucagon secretion from αZnT8Tg islets is impaired in vitro.
Isolated islets were incubated at 1 mM or 17 mM glucose for 1 h.
Released glucagon was measured using an HTRF assay. Transgenic
islets secreted significantly less glucagon compared to control when
incubated at 1 mM glucose. Data are mean ± SEM, n = 4 separate
experiments involving islets from 3 to 4 mice per genotype, *P < 0.05
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using the granule-accumulated Zn2+ probe, Zinpyr4 [17]
or in the cytosol with the recombinant-targeted Förster
resonance energy-based probe, eCALWY4 [27]. Since in-
dividual α cells could not readily be identified in primary
mouse islets from the transgenic animals, these experi-
ments were performed using the clonal α-cell line,
αTC1-9 [29]. Whereas granular Zn2+ was significantly
increased in the presence of exogenously-expressed
ZnT8, as indicated by a substantial increase in the fluor-
escence of Zinpyr4 (Fig. 5), free Zn2+ concentrations
tended to be lowered in the cytosol after ZnT8 over-
expression (Fig. 6).
Discussion
In this report our aim was to overexpress ZnT8 in the
pancreatic α-cell in order to investigate the effect on glu-
cagon secretion. The results, which demonstrate inter-
esting parallels with respect to our findings in αZnT8
null animals [17], reveal that overexpression of ZnT8 in
the α-cell has no effect on glucose homeostasis or insu-
lin sensitivity, as assessed by intraperitoneal tolerance
tests. By contrast, increased α-cell ZnT8 levels strongly
affect responses to hypoglycaemia, as studied in hyperin-
sulinaemic clamps, as well as glucagon secretion in re-
sponse to low glucose both in vivo and in vitro. The
findings from the transgenic mouse with respect to
glucagon release are thus reciprocal to those obtained in
αZnT8 null mice and further reinforce the view that
ZnT8 has an important role in the α-cell in regulating
glucagon secretion.
Measured by qPCR in FACS-purified α-cells from
αZnT8Tg mice, human ZnT8 mRNA levels were ap-
proximately 0.6 times those of β-actin (Actb) mRNA
(Fig. 1c). This value is similar to that measured for the
murine ZnT8 homologue [17]. Assuming similar ampli-
fication efficiencies of the primers used for human and
rodent ZnT8, and homogeneous expression across the
entire α-cell population, the above measurement implies
roughly equivalent levels of mouse and human ZnT8
mRNA in transgenic α-cells, i.e. a doubling of the en-
dogenous level in wild type mice. We note, however, that
though the more active (W325) human ZnT8 variant
Fig. 5 Vesicular free Zn2+ assessment in αTC1.9 cells. αTC1.9 cells transfected with an expression vector encoding ZnT8 (αTC1.9 ZnT8) or empty
vector (αTC1.9 EV) were incubated with ZinPyr4 (1 μM) for 20 min. before imaging. a Representative fields of view for αTC1.9 EV and αTC1.9 ZnT8
cells. b ZinPyr4 fluorescence intensity was determined on ten fields of view for two acquisitions, with constant light source power and exposure
time. c Average traces. Acquisitions were performed under perifusion with imaging buffer and with addition as stated (TPEN 50 μM - pyrithione
(5 μM)/Zn2+ (100 μM)). Fluorescence intensity ratio was normalised as F/Fmax
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was used in the present studies [7], the relative trans-
porter activities of this versus the rodent (Q325) variant
are not known, precluding a more accurate estimate of
the extent of the increase in ZnT8 activity in αZnT8Tg
versus control α-cells.
Likewise, efforts to quantify the degree of human ZnT8
expression in the α-cell at the protein level were unsuc-
cessful. These included immunostaining followed by islet
dissociation, FACS analysis, and confocal imaging. Both
approaches revealed limited affinity or selectively of the
available antibodies towards human ZnT8 (Table 2). Thus,
staining of islets did not reveal human ZnT8-positive pop-
ulations in the face of high background staining (results
not shown). Likewise, under FACS analysis, the entire
population of islet cells from either control or αZnT8Tg
mice was found to be positive for human ZnT8 (results
not shown). Similar findings were made over a range of
primary and secondary antibody concentrations, and sug-
gest at least partial reactivity of the anti-human antibody
towards murine ZnT8. An anti-c-Myc antibody, aimed to
detect the epitope tag present at the C-terminus of the
ZnT8 transgene was also tested. Again, the staining was
too weak across a range of primary antibody concentra-
tions for meaningful quantitation (results not shown).
The results here complement those of a similar recent
study from our laboratory [23]. In this earlier study, hu-
man ZnT8 was over-expressed in the adult β-cell using
an insulin promoter-dependent Tet-On system. In the
latter model, glucose-induced insulin secretion from
βZnT8Tg mice was impaired whereas Zn2+ release dur-
ing stimulated exocytosis was elevated. A similar in-
crease in granular Zn2+ content and secretion of these
ions might reasonably be expected from αZnT8Tg α-
cells especially since targeted deletion of ZnT8 led to a
reduction of granular Zn2+ levels in both the α [17] and
β [23] cell. Likewise, changes in cytosolic free Zn2+ cells
levels may occur after ZnT8 overexpression (as observed
in β cells after the deletion of the transporter) [32]. Mea-
surements using targeted Zn2+ probes [33] revealed the
expected changes in compartmentalised Zn2+ upon
ZnT8 over-expression in the α cell line αTC1-9 (Figs. 5
and 6). Thus, it seems likely that ZnT8 over-expression
also increased granular Zn2+ in the primary α cell in the
transgenic mice. Future studies, in which the latter
mouse line is crossed to a reporter strain allowing the
expression and identification of a fluorescent marker in
the α cell [17], will be required to confirm these
observations.
Fig. 6 Cytosolic free Zn2+ concentration measured using eCALWY-4 in αTC1.9 cells. αTC1.9 cells were co-transfected with an eCALWY-4 construct
and with an expression vector for ZnT8 (αTC1.9 ZnT8) or empty vector (αTC1.9 EV). a Representative ratiometric images, obtained at steady state
(R), under perfusion with the Zn2+ chelator N,N,N’,N’-tetrakis (2 pyridylmethyl) ethylenediamine (TPEN) 50 μM (Rmax) and under perfusion
with pyrithione (5 μM)/Zn2+ (100 μM) (Rmin). b Representative traces obtained. Fluorescence intensity ratio was normalised according to
the formula: (R-Rmin)/(Rmax-Rmin). c Using R, Rmin and Rmax values, cytosolic free Zn
2+ concentrations were calculated for αTC1.9 EV cells
(2 experiments - 7 cells) and αTC1.9 ZnT8 cells (2 experiments - 20 cells). d Percentage of cells presenting with a saturated sensor response
(ie. cytosolic Zn2+ concentrations > 8 nM)
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In addition to changes in cell function, we do not
exclude the possibility that subtle changes (lowering) in
α cell mass may also contribute to decreased glucagon
release in αZnT8Tg mice, potentiating the impact on the
acute release of the hormone observed after islet isola-
tion (Fig. 4). Importantly, such changes may lead to
alterations in the activity of signalling pathways the con-
trol cell survival [33]. Similarly, changes in the expres-
sion of genes involved in glucose sensing by α-cells (e.g.
glucokinase, Gck, or subunits of ATP-sensitive K+ chan-
nels, i.e. Kcnj11or Abcc8, etc.) [34, 35] may also contrib-
ute to altered glucagon release from αZnT8Tg mouse
islets. We note, however, that alterations in the latter
were not observed after ZnT8 ablation [8] or overex-
pression [23] from β cells. Changes in the expression of
genes controlling glucagon synthesis or processing of
the prohormone (e.g. Pcsk1 or Pcsk2) would appear un-
likely given unaltered total glucagon levels in αZnT8Tg
islets (not shown).
Interestingly, over-expression of ZnT8 in the β cell
also substantially inhibited glucose-induced insulin
release both in vivo and from isolated islets [23]. In both
β and α cells this might reflect slower dissolution of
crystalline or other higher-order forms of the cargo hor-
mones within secretory granules, impairing the forma-
tion and subsequent release of dimers or monomers
through a diffusion-limiting pore [36]. βZnT8Tg mice
nonetheless displayed enhanced glucose clearance
compared to wild-type animals [23]. This change may
be the consequence of increased Zn2+ release and an
insulinomimetic action of these ions on target tissues
[33], as well as impaired clearance of insulin by the
liver [10]. By contrast, the impaired hypoglycemic re-
sponse observed in αZnT8Tg mice was largely in line
with the observed decrease in plasma glucagon levels,
arguing that any increase in Zn2+ co-release from the
α cell is insufficient to compensate for the lowered
levels of the latter hormone. In any case, we note that
glucagon and Zn2+ are reported to exert opposing
effects on glycolysis in the isolated liver cells, whilst
exerting a similar, activating effect on glycogen break-
down [37].
Conclusions
In direct contrast to the activating effect of ZnT8 deletion
in α cells [17], overexpression of the transporter in these
cells inhibits glucagon release under hypoglycaemic condi-
tions. The present results thus reinforce the view that
ZnT8 inhibition may be useful as a means to enhance glu-
cagon release and hypoglycemic responses in the context
of T1D. Conversely, activation of ZnT8 in the α-cell, and
inhibition of glucagon secretion, may be beneficial in
T2D, complementing the effect of ZnT8 overexpression in
β cells to enhance insulin action [23]. Our findings also
suggest that differences in the impact on T2D risk
between rare [12] and more common [2] variants in the
human SLC30A8/ZnT8 gene [13] might be explained in
part by varying actions on glucagon release.
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